

Promise of better treatment for diabetes in Greenland after discovery of widespread genetic variant

November 16 2022



(A) Screening of variants from whole genome sequencing in MODY genes. Either all variants or only showing moderate or high impact. Novel variants are variants without a dbSNP id or otherwise reported in literature. (B) Local ancestry haplotypes at the c.1108G>T variant region for all 87 admixed and c.1108G>T heterozygous individuals. Each individual is represented with two lines, one for the c.1108G>T haplotype and one for the WT haplotype. The vertical line represents the position of the c.1108G>T variant. (C) Frequency of T2D separated by genotype and effect size (OR) with 95% CI below. (D) Mean



value of HbA1c separated by genotype and effect size with 95% CI below. (E) Serum insulin measurements at fasting (0 min), 30-min, and 2-h after glucose ingestion of the follow-up participants. (F) Plasma glucose measurements at fasting (0 min), 30-min, and 2-h after glucose ingestion of the follow-up participants. In E and F errors are mean \pm SEM. Credit: *The Lancet Regional Health - Europe* (2022). DOI: 10.1016/j.lanepe.2022.100529

Not all diabetes is the same, and it goes well beyond the two main classifications, type 1 and type 2. Monogenic diabetes refers to forms of diabetes caused by single genetic variations. Maturity-onset diabetes of the young (MODY) is the most common clinical subdivision of monogenic diabetes, with diabetes typically arising in young adulthood.

Now, an international team of researchers have discovered a new variant of the HNF1A gene, which can cause MODY that accounts for almost 7% of all cases of diabetes in Greenland and is found nowhere else in the world.

"We were excited to make this discovery of a new genetic variant that is responsible for close to 7% all cases of diabetes in Greenland. Discoveries like these, which was made possible thanks to a generous collaboration with the Greenlandic people, help us better understand the complexity of diabetes," says Professor Torben Hansen from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. He led the research together with Professors Anders Albrechtsen and Ida Moltke from the Department of Biology at the University of Copenhagen.

Potential for precision medicine

People with HNF1A-MODY are often misdiagnosed with either type 1



or type 2 diabetes and given medication that is not effective. Instead, HNF1A-MODY is most effectively treated with tablet therapy with sulfonylurea, which is rarely used today in the treatment of type 2 diabetes. Therefore, researchers are hopeful that this discovery will pave the way for precision treatment in Greenland. As monogenic diabetes is inherited, genetic tests can reveal if other family members also have the same type of diabetes.

"This discovery is good news for the treatment of diabetes in Greenland, because most people with MODY can be treated with a simple and cheap tablet treatment and avoid insulin and other more complex forms of diabetes treatment. Therefore, we now offer genetic testing for MODY to all our patients with diabetes, and when we find people with HNF1A-MODY, we systematically offer that <u>family members</u> are also tested," says senior physician and professor Marit Eika Jørgensen at the Steno Diabetes Center Greenland. Marit Eika Jørgensen coordinated the research in Greenland, which involved more than 4,000 Greenlanders.

Monogenic diabetes more common in Greenland than in Western populations

Together with a previously described high-impact variant, the TBC1D4 variant, close to 1 in 5 Greenlanders with diabetes are carriers of common high-impact variants. Monogenic diabetes is, therefore, far more frequent in Greenland than in Western populations, where monogenic diabetes is estimated to account for only around 1 in 50 cases of <u>diabetes</u>.

"This discovery clearly demonstrates how <u>common diseases</u> are much more complex than we previously thought. Thanks to the breakthroughs in <u>genetic research</u> and data science capabilities, many people around the world may benefit from new personalized medicine approaches that take



ancestral, genetic, and environmental backgrounds into account," says Ph.D. Student Anne Cathrine Baun Thuesen from CBMR, who was cofirst author together with Frederik Filip Stæger from the Department of Biology at the University of Copenhagen.

The study has just been published in *The Lancet Regional Health—Europe*.

More information: Anne Cathrine Baun Thuesen et al, A novel spliceaffecting HNF1A variant with large population impact on diabetes in Greenland, *The Lancet Regional Health—Europe* (2022). <u>DOI:</u> <u>10.1016/j.lanepe.2022.100529</u>

Provided by University of Copenhagen

Citation: Promise of better treatment for diabetes in Greenland after discovery of widespread genetic variant (2022, November 16) retrieved 27 June 2024 from <u>https://medicalxpress.com/news/2022-11-treatment-diabetes-greenland-discovery-widespread.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.